Contractual Agreement, Pharmacy Benefits Management Services (HealthSelect of Texas)

All five models reached this verdict. Section 2.3 has Express Scripts agree to act as a fiduciary in good faith with candor and due diligence, and section 5.4(b) on page 7 adds a warranty of utmost good faith, loyalty, candor and skill. That is an express fiduciary undertaking, which is rare in pharmacy benefit contracts, but the duty is framed around performance of the contract rather than loyalty owed solely to the plan and its members. There is no duty to disclose every form of direct and indirect compensation and no disgorgement remedy for value retained in breach, so the clause is weaker than the model contract published by Mark Cuban and collaborators.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Four of five models read this as partial; Gemini 3.1 Pro called it missing because there is no named officer certification. Article 16 on page 22 requires immediate written disclosure of actual or perceived conflicts of interest, and section 4.1(a) and 4.1(e) on page 4 confine the vendor's compensation to what the Fee Schedule lists and route manufacturer program fees to ERS. What is absent is a standing account of all direct and indirect compensation, any schedule of affiliate ownership touching plan claims, disclosure of payments to consultants or brokers, and a quarterly or annual certification by a named officer. Disclosure exists but is event driven rather than a certified accounting, which is the partial verdict.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

Three of five models read this as partial; Gemini 3.1 Pro and Kimi K3 called it missing because the exhibit list on page 34 contains no ownership or affiliate disclosure exhibit and the insurance pages are not a disclosure document. Section 8.1 on page 10 requires immediate notice of any merger, acquisition or change of ownership or control, section 4.1(i) on page 4 names Accredo Health Group, Inc. and Express Scripts Specialty Distribution Services, Inc. as the affiliated specialty pharmacies, and the insurance declaration pages at pages 55 to 58 happen to list many related entities including MATRIX GPO, LLC. None of that is a signed exhibit that maps every owner, affiliate, purchasing entity and rebate aggregator with a duty to refresh it within 30 days. The re-read confirms the disclosure is real but incidental, so the majority verdict stands with low confidence because the two missing votes make a fair point.

Model votes: Kimi K3 missing, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

All five models reached this verdict. The rebate definition at section 4.1(i) on pages 5 and 6 is broader than most contracts of its era, sweeping in price protection dollars, price concessions, discounts and any other remuneration, and section 4.1(e) on page 4 folds manufacturer program fees into the same bucket. The definition is then limited on page 6 to amounts received under a contract with a pharmaceutical manufacturer and related to utilization of formulary drugs, so revenue routed through a purchasing entity or tied to non formulary drugs sits outside it. Specialty is defined by which affiliate dispenses rather than by economic function, and generic and pharmacy are not defined at all in the base text.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Four of five models read this as partial; Gemini 3.1 Pro voted good because the clause says all rebates and the definition is broad. Section 4.1(h) on page 5 commits Express Scripts to pay all defined Rebates and all federal subsidies to ERS at least quarterly, which is a genuine pass through promise. It falls short of the model in three ways: the promise is qualified by the words as set forth herein and in Exhibit D, and page 5 says rebates are paid at the applicable rate described in the Fee Schedule, so the text does not itself establish one hundred percent; the definition on page 6 reaches only manufacturer contract payments tied to formulary utilization; and there is no 30 day settlement deadline or closed list of excludable claims. Exhibit D is a cover sheet on page 39, so the operative rate cannot be read.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro good

Four of five models read this as unclear; Grok 4.6 voted missing because no clause in the base text requires acquisition cost pricing. Pages 3 and 4 define PBM Mail Pharmacy and PBM Specialty Pharmacy as channels owned by Express Scripts or its affiliates, so affiliate dispensing is built into the design, and section 4.1(a) on page 4 places every compensation and reimbursement schedule in the Fee Schedule attached as Exhibit D. Exhibit D is present only as the cover sheet on page 39; the document says the schedule exists but its text is not posted. Because the pricing method for affiliate claims lives in a document that is referenced but withheld from the posted text, the item is unclear rather than missing.

No verbatim quote is available for this clause.

Model votes: Kimi K3 unclear, Grok 4.6 missing, GPT 5.6 Sol unclear, Claude Opus 5 unclear, Gemini 3.1 Pro unclear

Four of five models read this as missing; Gemini 3.1 Pro voted unclear on the theory that a ceiling might sit in Exhibit D. The substantive votes overrule that, because the base agreement never points to the Fee Schedule for any ceiling and does not use the concept at all. Article 4 on page 4 fixes Medi-span as the AWP pricing source and constrains MAC changes, but nothing caps a claim at a published benchmark or a transparent cash price in any channel, and nothing tests cost claim by claim. The amendments, supplement and service addendum are silent as well.

No verbatim quote is available for this clause.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro unclear

All five models reached this verdict. No provision protects a member from paying more through the plan than the pharmacy cash price, and the words cash price, usual and customary, accumulator and out of pocket maximum do not appear in the contractual text. Section 9.8 on page 12 compensates a participant for vendor error and the service addendum spreads Medicare Part D cost sharing over monthly invoices, but neither counts a cash purchase toward the deductible or bars accumulator adjustments. The subject is absent from every document read.

No verbatim quote is available for this clause.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing

Three of five models read this as partial; GPT 5.6 Sol voted bad because the clause affirmatively lets the vendor change MAC pricing under an ordinary course standard, and Gemini 3.1 Pro voted missing because none of the model's governance elements appear. Section 4.1(d) on page 4 addresses MAC pricing and limits changes to the ordinary course of business with a test protecting retail pharmacy participation, which is a real if soft guardrail. It does not require a single list for what the plan pays and what pharmacies are paid, does not require disclosure of the list, sets no update schedule and gives pharmacies no appeals path with timelines. The subject is addressed with narrower rights than the model, which is the definition of partial.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol bad, Claude Opus 5 partial, Gemini 3.1 Pro missing

Four of five models read this as unclear; Grok 4.6 voted missing because no sentence in the base text bars or permits a spread. The word spread never appears. Section 4.1(a) on page 4 commits the reimbursement schedule and administrative fees to the Fee Schedule attached as Exhibit D, and section 4.1(f) on page 5 shows the claims flow, with Express Scripts paying pharmacies first and then being reimbursed by ERS as provided in the RFP. Whether the reimbursement equals what the pharmacy was paid plus a disclosed fee, or is a guaranteed discount arrangement that lets the vendor keep a difference, is decided entirely inside Exhibit D and the RFP, which are present only as cover sheets on pages 36 and 39. The pricing method is referenced but withheld, so the item is unclear.

No verbatim quote is available for this clause.

Model votes: Kimi K3 unclear, Grok 4.6 missing, GPT 5.6 Sol unclear, Claude Opus 5 unclear, Gemini 3.1 Pro unclear

All five models reached this verdict. The contract never mentions group purchasing organizations, rebate aggregators or purchasing coalitions, and no clause routes purchase discounts, volume credits or supplier payments received by such entities to the plan. The rebate definition on pages 5 and 6 reaches only remuneration received by the PBM under a contract with a pharmaceutical manufacturer, so revenue collected by a related purchasing entity sits outside the pass through duty by construction. The insurance pages at pages 55 to 58 list MATRIX GPO, LLC among the named insureds, which shows such an affiliate exists, yet nothing requires its revenue to flow to ERS.

No verbatim quote is available for this clause.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing

All five models reached this verdict. ERS holds a real approval right: section 4.1(c) on page 4 requires written ERS approval of any material change to plan design including the formulary, and section 4.1(h) on page 5 requires prior approval by ERS representatives for formulary changes. The same sentence names manufacturer rebate arrangements as an accepted reason to change the formulary, which is the incentive the model contract exists to neutralize, and the formulary remains the PBM's own list. There is no lowest net cost analysis with each change and no quarterly report of utilization management outcomes by drug.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

All five models reached this verdict. No provision imposes a lowest net cost standard on formulary decisions for this plan, requires an annual comparison against the vendor's whole book of business, or requires disclosure when a drug is placed above a cheaper equivalent. Section 4.1(h) on page 5 allows a formulary management program with cost containment initiatives subject to ERS review, which is a process right rather than a cost standard, and section 31.6 on page 29 compares aggregate contract pricing across customers rather than formulary economics. Nothing in the amendments, supplement or service addendum fills the gap.

No verbatim quote is available for this clause.

Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing

Three of five models read this as partial; Gemini 3.1 Pro and Kimi K3 called it missing because none of the model's four protections appears. The re-read supports both camps. Section 5.4(d) on page 7 gives ERS sole discretion to implement an alternate retail network with a duty of cooperation, and section 4.1(d) on page 4 bars MAC changes that would discourage retail pharmacy participation, so the plan has some network leverage. But there is no statement that claims are final when adjudicated, no bar on retroactive clawbacks, no bar on volume conditioned reimbursement, no anti steering rule even though affiliated mail and specialty pharmacies are named on pages 3 and 4, and no any willing pharmacy right. The majority verdict stands because the subject is touched, with low confidence because the protections that matter most are absent.

Model votes: Kimi K3 missing, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing

All five models reached this verdict. Section 31.6 on page 29 is a genuine most favored pricing clause: if Express Scripts gives a similar or smaller government or unaffiliated commercial customer more generous aggregate pricing, the contract shall be amended at ERS' sole option to give equivalent advantage, and the vendor must notify ERS and document the determination. Its limits are that the comparison is measured in the aggregate rather than line by line, only customers of similar size or smaller count, and Express Scripts itself decides whether a comparative agreement is more generous. There is no annual independent market check with a meet, credit or release remedy.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Three of five models read this as partial; Claude Opus 5 and Kimi K3 voted good because the audit right is unusually broad. Section 15.5 on page 18 gives ERS an absolute audit right that expressly reaches the vendor's contracts with pharmaceutical manufacturers, section 15.6 adds Texas Insurance Code 1551.067 access to facilities, records and subcontractor agreements and shifts audit costs to the vendor when errors exceed $50,000, section 5.7 on page 9 gives ERS on premises access to claims data, and section 15.13 on page 19 says nothing in the proposal narrows these rights. Three limits keep it short of the model: third party auditors must sign a non disclosure agreement with the vendor, rebate agreement audits under section 15.12 on page 19 are limited to the portions an approved auditor deems necessary and scheduled by agreement, and section 14.3 on page 16 lets the vendor withhold third party pricing data as Third-Party IP. There is no pre adjudication claims access. A strong audit clause with real carve outs is partial.

Model votes: Kimi K3 good, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 good, Gemini 3.1 Pro partial

Three of five models read this as partial; Kimi K3 voted good because ownership, non reuse and portability are all present, and GPT 5.6 Sol voted bad because the business associate agreement lets the vendor keep de-identified data forever. Section 13.6 on page 14 makes confidential information, which section 13.4 on page 13 says includes all claims and membership records, the exclusive property of ERS, and section 21.2 on page 26 requires delivery of all ERS related records and data at no cost in a format that needs no specialized software. Against that, section 14.2 on page 16 reserves systems, methodologies and standard reporting to the vendor, section 3.1(2) of the business associate agreement on page 45 permits Express Scripts to de-identify protected health information and maintain it indefinitely, and the service addendum lets participant contact data go to a third party supplier. Ownership of the records is clear while reuse of derived data is not barred, which is weaker than the model.

Model votes: Kimi K3 good, Grok 4.6 partial, GPT 5.6 Sol bad, Claude Opus 5 partial, Gemini 3.1 Pro partial

All five models reached this verdict. Section 5.5 on page 7 incorporates performance guarantees as Exhibit E, which appears in the base document only as the cover sheet on page 40. Amendment 2 replaces that exhibit with First Amended and Restated Performance Guarantees, and Amendment 2 page 4, where those guarantees appear, is fully redacted. Whether the guarantees are measured quarterly on plan specific data, reconciled in cash, or paid dollar for dollar rather than as capped credits cannot be read.

No verbatim quote is available for this clause.

Model votes: Kimi K3 unclear, Grok 4.6 unclear, GPT 5.6 Sol unclear, Claude Opus 5 unclear, Gemini 3.1 Pro unclear

All five models reached this verdict. Article 9 gives ERS liquidated damages of up to $10,000.00 per default or per calendar day without proving actual damages, section 4.1(g) on page 5 lets ERS offset sums owed against the vendor's fees, and Article 11 on page 12 makes all remedies cumulative. Termination for cause is immediate in ERS' sole opinion under section 2.4(a) on page 2. The remedy is discretionary rather than self executing, the figure is a ceiling rather than a schedule, a notice and cure period generally applies, and there is no defined two strikes exit after a repeat breach or regulatory integrity failure. The performance guarantee credits themselves sit in the redacted Amendment 2 page 4.

Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial

Three of five models read this as good; GPT 5.6 Sol voted bad and Grok 4.6 voted partial because the service addendum says Express Scripts shall give 30 days written notice before changing the pricing structure of the Medicare Prescription Payment Plan program. Section 2.6 on page 2 permits change only by a written agreement executed by both parties, section 4.1(b) on page 4 holds the Fee Schedule unchanged for the term absent mutual written agreement, and the two amendments and the supplement in this record were in fact signed by both sides. The service addendum sentence on page 2 of that document sits directly beneath a sentence saying program changes after the first year require mutual written agreement, so it reads as a notice duty layered on consent rather than a unilateral repricing right, but the two dissenters are right that the drafting is loose and covers a fee whose amount is redacted. The majority verdict stands with reduced confidence.

Model votes: Kimi K3 good, Grok 4.6 partial, GPT 5.6 Sol bad, Claude Opus 5 good, Gemini 3.1 Pro good

Four of five models read this as good; Gemini 3.1 Pro voted partial because the text does not expressly say earned amounts are never forfeited. Section 2.4 on page 2 lets ERS terminate for cause immediately, without cause on ninety days notice, by mutual agreement, or if the Board does not approve funds, and no termination fee appears anywhere in the documents. Section 4.3 on page 6 requires a pro rata refund of prepaid fees within two business days, section 4.1(h) on page 5 continues rebate payments until ERS has received all such compensation, and Article 21 on page 26 requires transition cooperation and delivery of records at no cost. Nothing conditions earned rebates on the contract continuing, so the model's protections are present.

Model votes: Kimi K3 good, Grok 4.6 good, GPT 5.6 Sol good, Claude Opus 5 good, Gemini 3.1 Pro partial

Four of five models read this as unclear; Grok 4.6 voted partial because the base text names the affiliated specialty pharmacies without defining specialty by function or setting a ceiling. Section 4.1(i) on page 4 defines PBM Specialty Pharmacy as Accredo Health Group, Inc., Express Scripts Specialty Distribution Services, Inc. and other affiliate pharmacies that primarily dispense Specialty Products, and Specialty Products is never defined. Every drug level rate, channel ceiling and any acquisition cost term for affiliate specialty claims sits in the Fee Schedule that section 4.1(a) incorporates as Exhibit D, present only as the cover sheet on page 39. The specialty pricing controls are referenced but their text is withheld, so the item is unclear.

No verbatim quote is available for this clause.

Model votes: Kimi K3 unclear, Grok 4.6 partial, GPT 5.6 Sol unclear, Claude Opus 5 unclear, Gemini 3.1 Pro unclear

Three of five models read this as partial; Claude Opus 5 and Kimi K3 voted good because the confidentiality article runs against the vendor and nothing bars ERS from releasing pricing, rebate or performance data. The re-read shows why the majority saw a limit. Section 13.1 on page 13 confirms ERS is subject to the Texas Public Information Act, and section 13.11 on page 15 tells the vendor to assume its reports may be public records and says ERS has no duty to advocate for the vendor's confidentiality claims, which is favorable. In the same section, ERS' auditors, advisors and consultants may use vendor materials only subject to a non disclosure agreement with the vendor, the vendor may label materials confidential or proprietary and gets notice and a right to argue to the Attorney General against release, and the service addendum is stamped Confidential Information with its fee redacted on page 5. Nothing restricts pharmacies from telling members about cheaper options, and Supplement 1 has the vendor supporting the federal gag clause attestation. A public records posture with vendor labelling rights and an NDA condition on advisors is partial, which sets the red flag.

Model votes: Kimi K3 good, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 good, Gemini 3.1 Pro partial